Morán Pascual E, Dicapua Sacoto C, Trassierra Villa M, Pontones Moreno J L, Ruiz Cerdá J L, Jiménez Cruz J F
Servicio de Urología, Hospital La Fe, Valencia, España.
Actas Urol Esp. 2010 Nov;34(10):854-9.
To describe the outcome of patients diagnosed of incidental prostate adenocarcinoma managed by watchful waiting.
We included patients with PSA< 4 ng/mL or higher with previous negative biopsy, who underwent surgery for BPH being diagnosed of incidental prostate adenocarcinoma. We performed a descriptive and retrospective study in patients with this diagnosis between 1992 and 2007. Salvage curative treatment was offered to those patients who progressed. Statistical analysis was performed using SPSS program. Progression variables were: age, preoperative and postoperative PSA, stage, Gleason score, prostate volume, initial treatment, PSA evolution and salvage treatment if necessary.
47 patients were diagnosed of incidental prostatic adenocarcinoma, finding an incidence of 4.25%. The medium follow up was 37 months. Of the patients who opted for watchful waiting, 72.5% remain on it. 11 patients progressed. Postoperative PSA and Gleason score showed up as prognostic variables of progression in T1a stage and postsurgery PSA did so in T1b patients.
Watchful waiting is a useful option in patients with incidental prostate adenocarcinoma and favourable prognostic criteria. Postoperative PSA and Gleason score can predict progression in T1a stage and postoperative PSA in T1b stage.
描述接受观察等待治疗的偶发性前列腺腺癌患者的治疗结果。
我们纳入了前列腺特异性抗原(PSA)<4 ng/mL或更高且先前活检阴性、因良性前列腺增生接受手术时被诊断为偶发性前列腺腺癌的患者。我们对1992年至2007年间诊断为此病的患者进行了描述性回顾性研究。对病情进展的患者提供挽救性根治性治疗。使用SPSS软件进行统计分析。进展变量包括:年龄、术前和术后PSA、分期、Gleason评分、前列腺体积、初始治疗、PSA演变情况以及必要时的挽救性治疗。
47例患者被诊断为偶发性前列腺腺癌,发病率为4.25%。中位随访时间为37个月。选择观察等待的患者中,72.5%仍在接受观察等待。11例患者病情进展。术后PSA和Gleason评分是T1a期进展的预后变量,术后PSA是T1b期患者进展的预后变量。
对于具有偶发性前列腺腺癌且预后标准良好的患者,观察等待是一种有用的选择。术后PSA和Gleason评分可预测T1a期的进展情况,术后PSA可预测T1b期的进展情况。